Transoral incisionless fundoplication with Medigus ultrasonic surgical endostapler (MUSE) for the treatment of gastro-esophageal reflux disease: outcomes up to 3 years.
Gastro-esophageal reflux disease
Medigus Ultrasonic Surgical Endostapler (MUSE)
Transoral incisionless fundoplication
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
19
02
2021
accepted:
29
10
2021
pubmed:
21
11
2021
medline:
7
6
2022
entrez:
20
11
2021
Statut:
ppublish
Résumé
Transoral incisionless fundoplication (TIF) with Medigus Ultrasonic Surgical Endostapler (MUSE) is a new intervention for treatment of gastro-esophageal reflux disease (GERD). We aimed at assessing the clinical, functional, and endoscopic effects of TIF by MUSE. Forty-six patients underwent TIF. Proton pump inhibitor (PPI) consumption, GERD-health-related quality of life (HRQL) and reflux symptom index (RSI) questionnaires, upper gastrointestinal (GI) endoscopy, esophageal 24-h pH-impedance recording, and high-resolution manometry (HRM) were done before TIF and scheduled 6 and 12 months later (HRM only at 6-month). PPI consumption and symptoms were then assessed yearly. Data up to 3 years are reported in this study (PP- and ITT-analysis). TIF was successfully performed in 45/46 patients; in one patient esophageal intubation was impossible. Perforation occurred in two cases. One patient required surgery within 6 months. Clinical follow-up was available for 42 patients at 6 months and 1 year, 35 patients at 2 years, and 31 patients at 3 years. At 1, 2, and 3 years, PPI consumption was stopped, respectively, in 64.3%, 62.9%, and 74.2% of cases (ITT-analysis: 58.7%, 56.4%, and 65.7%). GERD-HRQL and RSI scores decreased at least 50%, respectively, in 71.5% and 76.2%, 71.4% and 68.6%, and 67.7% of cases (ITT-analysis: 65.2% and 69.6%, 64.1% and 61.5%, and 60%). A significant improvement of both scores was observed up to 3 years. 6-month and 1-year functional follow-up were possible in 31 and 20 patients. HRM showed significant increase of the median lower esophageal sphincter length and rate of peristaltic waves. Esophageal pH-impedance recording found significantly fewer acid, proximal and total refluxes, and percentage of esophageal pH < 4 total time at 6 months, but not at 1 year. TIF by MUSE significantly improved symptoms and PPIs consumption up to 3 years. However, esophagitis still persisted in one-third of cases at 1 year and functional improvement at 6 months was not confirmed at 1 year. Severe complications requiring surgery occurred in two cases. GOV: ID: NCT03669874.
Sections du résumé
BACKGROUND
Transoral incisionless fundoplication (TIF) with Medigus Ultrasonic Surgical Endostapler (MUSE) is a new intervention for treatment of gastro-esophageal reflux disease (GERD). We aimed at assessing the clinical, functional, and endoscopic effects of TIF by MUSE.
METHODS
Forty-six patients underwent TIF. Proton pump inhibitor (PPI) consumption, GERD-health-related quality of life (HRQL) and reflux symptom index (RSI) questionnaires, upper gastrointestinal (GI) endoscopy, esophageal 24-h pH-impedance recording, and high-resolution manometry (HRM) were done before TIF and scheduled 6 and 12 months later (HRM only at 6-month). PPI consumption and symptoms were then assessed yearly. Data up to 3 years are reported in this study (PP- and ITT-analysis).
RESULTS
TIF was successfully performed in 45/46 patients; in one patient esophageal intubation was impossible. Perforation occurred in two cases. One patient required surgery within 6 months. Clinical follow-up was available for 42 patients at 6 months and 1 year, 35 patients at 2 years, and 31 patients at 3 years. At 1, 2, and 3 years, PPI consumption was stopped, respectively, in 64.3%, 62.9%, and 74.2% of cases (ITT-analysis: 58.7%, 56.4%, and 65.7%). GERD-HRQL and RSI scores decreased at least 50%, respectively, in 71.5% and 76.2%, 71.4% and 68.6%, and 67.7% of cases (ITT-analysis: 65.2% and 69.6%, 64.1% and 61.5%, and 60%). A significant improvement of both scores was observed up to 3 years. 6-month and 1-year functional follow-up were possible in 31 and 20 patients. HRM showed significant increase of the median lower esophageal sphincter length and rate of peristaltic waves. Esophageal pH-impedance recording found significantly fewer acid, proximal and total refluxes, and percentage of esophageal pH < 4 total time at 6 months, but not at 1 year.
CONCLUSION
TIF by MUSE significantly improved symptoms and PPIs consumption up to 3 years. However, esophagitis still persisted in one-third of cases at 1 year and functional improvement at 6 months was not confirmed at 1 year. Severe complications requiring surgery occurred in two cases.
CLINICALTRIALS
GOV: ID: NCT03669874.
Identifiants
pubmed: 34799745
doi: 10.1007/s00464-021-08860-w
pii: 10.1007/s00464-021-08860-w
doi:
Substances chimiques
Proton Pump Inhibitors
0
Alprostadil
F5TD010360
Banques de données
ClinicalTrials.gov
['NCT03669874']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5023-5031Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Huang X, Chen S, Zhao H, Zeng X, Lian J, Tseng Y, Chen J (2017) Efficacy of transoral incisionless fundoplication (TIF) for the treatment of GERD: a systematic review with meta-analysis. Surg Endosc 31:1032–1044. https://doi.org/10.1007/s00464-016-5111-7
doi: 10.1007/s00464-016-5111-7
pubmed: 27495332
McCarty TR, Itidiare M, Njei B, Rustagi T (2018) Efficacy of transoral incisionless fundoplication for refractory gastroesophageal reflux disease: a systematic review and meta-analysis. Endoscopy 50:708–725. https://doi.org/10.1055/a-0576-6589
doi: 10.1055/a-0576-6589
pubmed: 29625507
Muls V, Eckardt AJ, Marchese M, Bastens B, Buset M, Devière J, Louis H, Rajan A, Daniel MA, Costamagna G (2013) Three-year results of a multicenter prospective study of transoral incisionless fundoplication. Surg Innov 20:321–330. https://doi.org/10.1177/1553350612459275
doi: 10.1177/1553350612459275
pubmed: 22968006
Witteman PBL, Strijkers R, de Vries E, Toemen L, Conchillo JM, Hameeteman W, Dagnelie PC, Koek GH, Bouvy ND (2012) Transoral incisionless fundoplication for treatment of gastroesophageal reflux diseases in clinical practice. Surg Endosc 26:3307–3315. https://doi.org/10.1007/s00464-012-2324-2
doi: 10.1007/s00464-012-2324-2
pubmed: 22648098
pmcid: 3472060
Roy-Shapira A, Bapaye A, Date S, Pujari R, Dorwat S (2015) Trans-oral anterior fundoplication: 5-year follow-up of pilot study. Surg Endosc 29:3717–3721. https://doi.org/10.1007/s00464-015-4142-9
doi: 10.1007/s00464-015-4142-9
pubmed: 25783833
pmcid: 4648975
Kim HJ, Kwon CI, Kessler WR, Selzer DJ, McNulty G, Bapaye A, Bonavina L, Lehman GA (2016) Long-term follow-up results of endoscopic treatment of gastroesophageal reflux disease with the MUSE
doi: 10.1007/s00464-015-4622-y
pubmed: 26537905
Trad KS, Barnes WE, Prevou ER, Simoni G, Steffen JA, Shughoury AB, Raza M, Heise JA, Fox MA, Mavrelis PG (2018) The TEMPO trial at 5 years: transoral fundoplication (TIF 2.0) is safe, durable, and cost-effective. Surg Innov 25:149–157. https://doi.org/10.1177/1553350618755214
doi: 10.1177/1553350618755214
pubmed: 29405886
pmcid: 5946656
Stefanidis G, Viazis N, Kotsikoros N, Tsoukalas N, Lala E, Theocharis L, Fassaris A, Manolakopoulos S (2017) Long-term benefit of transoral incisionless fundoplication using the Esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy. Dis Esophagus 30:1–8. https://doi.org/10.1111/dote.12525
doi: 10.1111/dote.12525
pubmed: 27868281
Testoni PA, Testoni S, Distefano G, Mazzoleni G, Fanti L, Passaretti S (2019) Transoral incisionless fundoplication with EsophyX for gastroesophageal reflux disease: clinical efficacy is maintained up to 10 years. Endosc Int Open 7:E647–E654. https://doi.org/10.1055/a-0820-2297
doi: 10.1055/a-0820-2297
pubmed: 31058207
pmcid: 6497496
Chimukangara M, Jalilvand AD, Melvin WS, Perry KA (2019) Long-term reported outcomes of transoral incisionless fundoplication: an 8-year cohort study. Surg Endosc 33:1304–1309. https://doi.org/10.1007/s00464-018-6403-x
doi: 10.1007/s00464-018-6403-x
pubmed: 30167944
Kauer WK, Roy-Shapira A, Watson D, Sonnenschein M, Sonnenschein E, Unger J, Voget M, Stein HJ (2009) Preclinical trial of a modified gastroscope that performs a true anterior fundoplication for the endoluminal treatment of gastroesophageal reflux disease. Surg Endosc 23:2728–2731. https://doi.org/10.1007/s00464-009-0479-2
doi: 10.1007/s00464-009-0479-2
pubmed: 19357915
Gweon TG, Matthes K (2016) Prospective randomized ex vivo trial to assess the ideal stapling site for endoscopic fundoplication with medigus ultrasonic surgical endostapler. Gastroenterol Res Pract 2016:ID3161738. https://doi.org/10.1155/2016/3161738
doi: 10.1155/2016/3161738
Testoni PA, Testoni S, Mazzoleni G, Pantaleo G, Cilona MB, Distefano G, Fanti L, Antonelli M, Passaretti S (2020) Transoral incisionless fundoplication with an ultrasonic surgical endostapler for the treatment of gastro-esophageal reflux disease: 12-month outcomes. Endoscopy 52:469–473. https://doi.org/10.1055/a-1124-3187
doi: 10.1055/a-1124-3187
pubmed: 32187630
Stefanidis D, Hope WW, Kohn GP, Reardon PR, Richardson WS, Fanelli RD, SAGES Guidelines Committee (2010) Guidelines for surgical treatment of gastroesophageal reflux disease. Surg Endosc 24(11):2647–2669. https://doi.org/10.1007/s00464-010-1267-8
doi: 10.1007/s00464-010-1267-8
pubmed: 20725747
Velanovich V (2007) The development of the GERD-HRQL symptom severity instrument. Dis Esophagus 20:130–134. https://doi.org/10.1111/j.1442-2050.2007.00658.x
doi: 10.1111/j.1442-2050.2007.00658.x
pubmed: 17439596
Schindler A, Mozzanica F, Ginocchio D, Peri A, Bottero A, Ottaviani F (2010) Reliability and clinical validity of the Italian reflux symptom index. J Voice 24:354–358. https://doi.org/10.1016/j.jvoice.2008.08.008
doi: 10.1016/j.jvoice.2008.08.008
pubmed: 19303740
Testoni PA, Testoni S, Mazzoleni G, Vailati C, Passaretti S (2015) Long-term efficacy of transoral incisionless fundoplication with Esophyx (TIF 2.0) and factors affecting outcomes in GERD pts followed for up to 6 years: a prospective single-center study. Surg Endosc 29:2770–2780. https://doi.org/10.1007/s00464-014-4008-6
doi: 10.1007/s00464-014-4008-6
pubmed: 25480624
Garg SK, Gurusamy KS (2015) Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev 11:CD003243. https://doi.org/10.1002/14651858.CD003243.pub3
doi: 10.1002/14651858.CD003243.pub3
Lundell L, Bell M, Ruth M (2014) Systematic review: laparoscopic fundoplication for gastro-esophageal reflux disease in partial responders to proton pump inhibitors. World J Gastroenterol 20:804–813. https://doi.org/10.3748/wjg.v20.i3.804
doi: 10.3748/wjg.v20.i3.804
pubmed: 24574753
pmcid: 3921489
Kelly JJ, Watson DI, Chin KF, Devitt PG, Game PA, Jamieson GG (2007) Laparoscopic Nissen fundoplication: clinical outcomes at 10 years. J Am Coll Surg 205:570–575. https://doi.org/10.1016/j.jamcollsurg.2007.05.024
doi: 10.1016/j.jamcollsurg.2007.05.024
pubmed: 17903731
Gunter RL, Shada AL, Funk LM, Wang X, Greenberg JA, Lidor AO (2017) Long-term quality of life outcomes following Nissen versus Toupet fundoplication in patients with gastroesophageal reflux disease. J Laparoendosc Adv Surg Tech A 27:931–936. https://doi.org/10.1089/lap.2017.0232
doi: 10.1089/lap.2017.0232
pubmed: 28737451
pmcid: 7875107